Evaluation of testicular tissue of adult rats treated with cisplatin incorporated into the liposome

Microscopy Research and Technique

Volumn 78, Issue 4, 2015, Pages 323-329

  Favareto, Ana Paula Alves ^a   Nogueira, Lázaro Cícero ^b   Pontes, Davi Abeid ^b   de Fátima Paccola Mesquita, Suzana ^c   Camargo, Isabel Cristina Cherici ^b  

^a UNIVERSIDADE DO OESTE PAULISTA UNOESTE   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Chemotherapeutic agent; Reproduction; Spermatogenesis; Synthetic vesicles

Indexed keywords

ANTHROPOMETRY; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; DRUG INTERACTIONS; RATS; TARGETED DRUG DELIVERY; TISSUE;

BODY WEIGHT; CHEMOTHERAPEUTIC AGENTS; CIS-PLATIN; CISPLATIN; DIPALMITOYL PHOSPHATIDYLCHOLINE; HUMAN MALIGNANCIES; REPRODUCTION; SIDE EFFECT; SPERMATOGENESIS; SYNTHETIC VESICLE;

LIPOSOMES;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANTINEOPLASTIC AGENT; CISPLATIN; DRUG CARRIER; LIPOSOME;

ANIMAL; CYTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICROSCOPY; PATHOLOGY; TESTIS; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG CARRIERS; HISTOCYTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; LIPOSOMES; MALE; MICROSCOPY; RATS, WISTAR; TESTIS;

EID: 84925356647     PISSN: 1059910X     EISSN: 10970029     Source Type: Journal    
DOI: 10.1002/jemt.22480     Document Type: Article

References (49)

1. Ahmad S. 2010. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers 7:543-66.
2. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. 2013. Liposome: Classification, preparation, and applications. Nanoscale Res Lett 8:102.
3. Ali BH, Al-Moundhri M, Tageldin M, Al Husseini IS, Mansour MA, Nemmar A, Tanira MO. 2008. Ontogenic aspects of cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol 46:3355-3359.
4. Anand H, Misro MM, Sharma SB, Prakash S. 2014. Protective effects of Eugenia jambolana extract versus N-acetyl cysteine against cisplatin-induced damage in rat testis. Andrologia 47:194-208. Doi: 10.1111/and.12247.
5. Ateşşahin A, Sahna E, Türk G, Ceribaşi AO, Yilmaz S, Yüce A, Bulmuş O. 2006a. Chemoprotective effect of melatonin against cisplatin-induced testicular toxicity in rats. J Pineal Res 41:21-27.
6. Ateşşahin A, Karahan I, Türk G, Gür S, Yilmaz S, Ceribaşi AO. 2006b. Protective role of lycopene on cisplatin-induced changes in sperm characteristics, testicular damage and oxidative stress in rats. Reprod Toxicol 21:42-47.
7. Ateşşahín A, Ceríbaşi AO, Yuce A, Bulmus O, Cikim G. 2007. Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin Pharmacol Toxicol 100:121-126.
8. Bieber AM, Marcon L, Hales BF, Robaire B. 2006. Effects of chemotherapeutic agents for testicular cancer on the male rat reproductive system, spermatozoa, and fertility. J Androl 27:189-200.
9. Camargo IC, Nogueira LC, Debus GV. 2001. Morphological evaluation of the testes in adult guinea pigs (Cavia porcellus, L) treated with oxamniquine incorporated into synthetic phospholipids (dimyristoil phosphatidylcoline) vesicles. Braz J Morphol Sci 18:29-34.
10. Camargo ICC, Nogueira LC, Pontes DA, Favareto APA, Mesquita SFP, Frei F. 2007. Morfometria e estereologia de ratos adultos tratados com ciclofosfamida incorporada ao lipossoma. Semina 27:11-22.
11. Ciarimboli G. 2014. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res 34:547-550.
12. Cvitkovic E. 1998. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev 24:265-281.
13. Einhorn LH, Foster RS. 2006. Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: Is there a preferred regimen? J Clin Oncol 24:2597-2598.
14. Favareto APA, Fernandez CDB, Silva DAF, Anselmo-Franci JA, Kempinas WDG. 2011a. Persistent impairment of testicular histology and sperm motility in adult rats treated with cisplatin at Peri-puberty. Basic Clin Pharmacol Toxicol 109:85-96.
15. Favareto APA, Toledo FC, Kempinas WDG. 2011b. Paternal treatment with cisplatin impairs reproduction of adult male offspring in rats. Reprod Toxicol 32:425-433.
16. Gameiro SR, Caballero JA, Hodge JW. 2012. Defining the molecular signature of chemotherapy mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing. Cancer Biother Radiopharm 27:23-35.
17. Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Chaudhry MA, Wahl R, Forastiere A, Gillison M. 2012. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Clin Cancer Res 18:1735-1742.
18. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, Peters AM, Stewart JS. 2001. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 12:493-496.
19. Hua S, Wu SY. 2013. The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol 4:143.
20. Huang HF, Pogach LM, Nathan E, Giglio W. 1990. Acute and chronic effects of cisplatinum upon testicular function in the rat. J Androl 11:436-445.
21. Ikeda M, Matsumoto K, Niibe Y, Satoh T, Fujita T, Iwamura M, Ishiyama H, Kotani S, Hayakawa K, Baba S. 2011. The radiotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin treatment is an effective therapeutic option in patients with advanced or metastatic bladder cancer. J Radiat Res 52:674-679.
22. Ishikawa T, Kamidono S, Fujisawa M. 2004. Fertility after high-dose chemotherapy for testicular cancer. Urology 63:137-140.
23. Iwamoto T. 2013. Clinical application of drug delivery systems in cancer chemotherapy: Review of the efficacy and side effects of approved drugs. Biol Pharm Bull 36:715-718.
24. Jung Y, Lippard SJ. 2007. Direct cellular responses to platinum-induced DNA damage. Chem Rev 107:1387-1407.
25. Kamel KM, Abd El-Raouf OM, Metwally SA, Abd El-Latif HA, El-Sayed ME. 2014. Hesperidin and rutin, antioxidant citrus flavonoids, attenuate cisplatin-induced nephrotoxicity in rats. J Biochem Mol Toxicol 28:312-319.
26. Kinkead T, Flores C, Carboni AA, Menon M, Seethalakshmi L. 1992. Short term effects of cis-platinum on male reproduction, fertility and pregnancy outcome. J Urol 47:201-206.
27. Kroon J, Metselaar JM, Storm G, van der Pluijm G. 2014. Liposomal nanomedicines in the treatment of prostate cancer. Cancer Treat Rev 40:578-584.
28. Lila AS, Kiwada H, Ishida T. 2014. Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin. Biol Phram Bull 37:206-211.
29. Lirdi LC, Stumpp T, Sasso-Cerri E, Miraglia SM. 2008. Amifostine protective effect on cisplatin-treated rat testis. Anat Rec (Hoboken) 291:797-808.
30. Liu D, He C, Wang AZ, Lin W. 2013. Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomedicine 8:3309-3319.
31. Marcon L, Hales BF, Robaire B. 2008. Reversibility of the effects of subchronic exposure to the cancer chemotherapeutics, bleomycin, etoposide and cisplatin, on spermatogenesis, fertility, and progeny outcome in the male rat. J Androl 29:408-417.
32. Nagayasu A, Uchiyama K, Kiwada H. 1999. The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv 40:75-87.
33. Ning YC, Cai GY, Zhuo L, Gao JJ, Dong D, Cui SY, Shi SZ, Feng Z, Zhang L, Sun XF, Chen XM. 2013. Beneficial effects of short-term calorie restriction against cisplatin-induced acute renal injury in aged rats. Nephron Exp Nephrol 124:19-27.
34. Nosko MM, Pivnyuk VM, Solyanik GI, Kulik GI, Todor IN, Momot VY, Melnikov OR, Ponomareva OV, Chekhun VF. 2010. Biodistribution analysis of cisplatin in liposomal form in animals with cisplatin-resistant and cisplatin-sensitive carcinoma. Exp Oncol 32:40-43.
35. Oberoi HS, Nukolova NV, Kabanov AV, Bronich TK. 2013. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 65:1667-1685.
36. Onoue S, Yamada S, Chan HK. 2014. Nanodrugs: Pharmacokinetics and safety. Int J Nanomedicine 9:1025-1037.
37. Pan H, Shen K, Wang X, Meng H, Wang C, Jin B. 2014. Protective effect of metalloporphyrins against cisplatin-induced kidney injury in mice. PLoS One 149:e86057.
38. Park JY, Jin KL, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, Nam JH. 2012. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecol Oncol 125:80-86.
39. Russell LD, Ettlin RA, Sinha-Hikim AP, Clegg ED. 1990. Histological and histopathological evaluation of the testis. In: The classification and timing of spermatogenesis. Russel LD, editor. Clearwater, FL: Cache River Press. pp. 63-118.
40. Russel LD, França LR. 1995. Building a testis. Tissue Cell 27:129-147.
41. Sawhney P, Giammona CJ, Meistrich ML, Richburg JH. 2005. Cisplatin-induced long-term failure of spermatogenesis in adult C57/BI/6J mice. J Androl 26:136-145.
42. Seethalakshmi L, Flores C, Kinkead T, Carboni AA, Malhotra RK, Menon M. 1992. Effects of subchronic treatment with cis-platinum on testicular function, fertility, pregnancy outcome, and progeny. J Androl 13:65-74.
43. Senkus E, Jassem J. 2011. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 37:300-311.
44. Takara K, Fujita M, Minegaki T, Yamamoto K, Takahashi M, Yokoyama T, Okumura K. 2012. Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells. Eur J Pharm Sci 45:272-281.
45. Torchilin VP. 1996. Affinity liposomes in vivo: Factors influencing target accumulation. J Mol Recognit 9:335-346.
46. Trasler JM, Hales BF, Robaire B. 1986. Chronic low dose cyclophosphamide treatment of adult male rats: Effect on fertility, pregnancy outcome and progeny. Biol Reprod 34:275-283.
47. Wang H, Kong L, Zhang J, Yu G, Lv G, Zhang F, Chen X, Tian J, Fu F. 2014. The pseudoginsenoside F11 ameliorates cisplatin-induced nephrotoxicity without compromising its anti-tumor activity in vivo. Sci Rep 4:4986.
48. Zalba S, Garrido MJ. 2013. Liposomes, a promising strategy for clinical application of platinum derivatives. Expert Opin Drug Deliv 10:829-844.
49. Zhao W, Zhuang S, Qi XR. 2011. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomedicine 6:3087-3098.